With few potentially epic drugs in the pharma pipeline right now, drug companies are seeking options to meet the needs of patients and increase revenue in the oral solid dosage (OSD) arena. Current strategies include exploring fixed dose combinations, reformatted injectables, and most intriguing, drugs that carry digital, ingestible sensors that can send information directly to a physician. Currently there is only one.
Portfolio expansion implementing lifecycle management strategies is less expensive than developing a new drug from scratch, as safety and efficacy have been previously established. In this whitepaper, Thermo Fisher Scientific shares ideas and opportunities that brand managers looking to expand their portfolios in a cost-effective manner—while helping patients —will find helpful.